Your search
Results 71 resources
-
Advances in the field of hematopoietic stem cell transplantation (HSCT) provide the opportunity for cure of malignant and nonmalignant diseases. The kinetics of immune reconstitution posttransplant and the immunosuppressive therapies used place HSCT recipients at risk for bacterial, viral, fungal, and other opportunistic infections. Identification of new donor sources of hematopoietic cells has improved accessibility to transplant but may lead to significant deficits in shortand long-term immune...
-
Background HCT leaves patients in a relative state of immune deficiency both during their initial transplant admission and for several years following discharge. NTM are generally harmless colonizers of the outside environment, but for immunocompromised patients, they can cause significant disease due to a paucity of T-cell defense. While routine prophylaxis against NTM is recommended for patients with low CD4 counts in certain clinical settings (eg, AIDS), this is not yet established for...
-
Hematopoietic transplantation is the preferred treatment for many patients with hematologic malignancies. Some patients may develop invasive fungal diseases (IFDs) during initial chemotherapy, which need to be considered when assessing patients for transplantation and treatment posttransplantation. Given the associated high risk of relapse and mortality in the post–hematopoietic stem cell transplantation (HSCT) period, IFDs, especially invasive mold diseases, were historically considered a...
-
Cytomegalovirus (CMV) infection remains an important cause of morbidity and mortality in allogeneic hematopoietic cell transplant (allo-HCT) recipients. CMV cell-mediated immunity (CMV-CMI) as determined by a peptide-based enzyme-linked immunospot (ELISPOT) CMV assay may identify patients at risk for clinically significant CMV infection (CS-CMVi).The CS-CMVi was defined as CMV viremia and/or disease necessitating antiviral therapy. CMV-CMI was characterized as high when the...
-
Vaccination is an effective strategy to prevent infections in immunocompromised hematopoietic stem cell transplant recipients. Pretransplant vaccination of influenza, pneumococcus, Haemophilus influenza type b, diphtheria, tetanus, and hepatitis B, both in donors and transplant recipients, produces high antibody titers in patients compared with recipient vaccination only. Because transplant recipients are immunocompromised, live vaccines should be avoided with few exceptions. Transplant...
-
Respiratory viral infections are common and can cause significant morbidity and mortality in pediatric patients undergoing hematopoietic cell transplantation (HCT). The prevalence of disease has been primarily identified from retrospective studies using standard-of-care specimens. The incidence of both asymptomatic respiratory viral detection and symptomatic respiratory viral detection in this high-risk population is not well described. We performed longitudinal, active, prospective...
-
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has become a widely used modality of therapy for a variety of malignant and nonmalignant diseases. Despite advances in pharmacotherapy and transplantation techniques, infection remains one of the most severe and frequently encountered complications of allo-HSCT.
-
Revaccination after receipt of a hematopoietic cell transplant (HCT) or cellular therapies is a pillar of patient supportive care, with the potential to reduce morbidity and mortality linked to vaccine-preventable infections. This review synthesizes national, international, and expert consensus vaccination schedules post-HCT and presents evidence regarding the efficacy of newer vaccine formulations for pneumococcus, recombinant zoster vaccine, and coronavirus disease 2019 in patients with...
-
Background Human parvovirus B19 (B19V) infection is associated with pure red cell aplasia (PRCA) in immunocompromised patients; however, the spectrum of manifestations associated with B19V in allogeneic hematopoietic stem cell transplantation recipients (alloHSCT) has rarely been reported. Methods In this study, we aimed to report clinical and immune features of B19V infection after alloHSCT. We retrospectively collected and analyzed clinical and microbiological data of all transplanted...
-
Hematopoietic cell transplant (HCT) and chimeric antigen receptor T-cell (CAR-T) therapy recipients are susceptible to multiple pulmonary complications that are caused by infectious and noninfectious processes. Numerous variables can be associated with specific pulmonary diseases including time from transplantation, presence of graft versus host disease (GVHD), underlying disease, and prolonged neutropenia and lymphocytopenia. Most pulmonary complications are infectious in origin, with...
Filter by our tag
GUIDELINES
- ASTCT Guidelines (2)
- ECIL Guidelines (1)
- ESCMID Guidelines (1)
TEXTBOOKS
ORGANISMS
-
BACTERIA
(8)
- C. difficile (3)
- Nocardia (2)
- Non-tuberculous Mycobacteria (2)
- Tuberculosis (2)
-
FUNGI
(3)
- Aspergillus (1)
- Candida (1)
- Cryptococcus (1)
- Mucormycosis (1)
- Pneumocystis (2)
-
PARASITES AND PROTOZOA
(1)
- Toxoplasmosis (1)
-
VIRUSES
(35)
- Adenovirus (4)
-
CMV
(10)
- Cell-Mediated Immunity Assays (2)
- Clinical (2)
- Letermovir (5)
- Maribavir (1)
-
COVID-19
(1)
- GUIDELINES (1)
- Treatments (1)
- Hepatitis E (1)
- HHV-6 (4)
- Influenza (2)
- Measles (2)
- Norovirus (1)
- Parvovirus B19 (1)
- Polyomaviruses (2)
- Respiratory Viruses (6)
- RSV (4)
DIAGNOSTICS
DRUGS AND THERAPIES
- Antifungals (3)
- Stewardship (1)
PREVENTION
- Vaccination (5)
HEME-ONC AND CELLULAR THERAPIES
- BMT-specific ID
- BMT Basics (1)
- BMT Noninfectious (1)
- CAR-T (2)
- Heme malignancies (1)
- Heme-onc prophylaxis (5)
- Neutropenia (3)
- PEDIATRIC (8)
- PTLD (1)
ARTICLE OF THE MONTH
- 2023 (1)
ATC 2024 Top Papers in TID
- VIRUSES (1)